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P U B L I S H E D B Y E L S E V I E R I N C .LettersRemote Ischemic
Conditioning Reduces
Myocardial Infarct Size
in STEMI Patients
Treated by ThrombolysisIn many developing nations, where primary percu-
taneous coronary intervention (PPCI) is not widely
available, ST-segment elevation myocardial infarc-
tion (STEMI) patients are still treated by thrombolysis
(1). However, because thrombolytic therapy is less
effective than PPCI at restoring blood ﬂow in an
infarct-related coronary artery, thrombolyzed STEMI
patients experience larger myocardial infarcts and arePatient Characteristics and AUC Cardiac Enzymes
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ngiotensin-converting enzyme; AUC ¼ area under the curve; Ca2þ ¼ calcium;
ence interval; CK-MB ¼ creatine kinase-myocardial band; IQR ¼ interquartile range;
te ischemic conditioning.more likely to develop heart failure. As such, there is
an urgent need for an innovative, easily applied, and
low-cost cardioprotective therapy. In this regard,
the heart can be protected against MI by simply
applying cycles of brief ischemia and/or reperfusion
to the arm or leg, which is termed remote ischemic
conditioning (RIC) (2). Therefore, we hypothesized
that RIC initiated on arrival at the hospital and
before thrombolysis could reduce enzymatic MI size
in STEMI patients (ERIC-LYSIS [Effect of Remote
Ischemic Conditioning in Heart Attack Patients] Study;
NCT02197117).
We performed a multicenter, single-blinded, ran-
domized controlled trial in the developing nation of
Mauritius. The Mauritian Ministry of Health and
Quality of Life provided ethical approval of the study.
All patients gave informed consent before entering
the study. Adult patients presenting with a STEMI
were randomly assigned to receive either RIC
(4  5-min cycles of upper arm cuff inﬂation to
200 mm Hg and deﬂation) or to the control group
(uninﬂated cuff placed on the upper arm for 40min) on
immediate arrival at the hospital. Exclusion criteria
included contraindications for thrombolysis, previous
MI, cardiac arrest, arteriovenous shunts, and pre-
existing treatment with nicorandil or glibenclamide.
Thrombolysis was achieved using streptokinase at a
dose of 1.5 million units over 60 minutes. The RIC or
control protocols were initiated before and continued
during thrombolysis, and did not delay the onset of
reperfusion. The pre-deﬁned primary endpoint was
enzymatic MI size as assessed by 24-h area under
the curve (AUC) serum troponin T and creatine
kinase-myocardial band (CK-MB), measured at 0, 6,
12, and 24 h.
BetweenMarch 2011 and November 2013, 519 STEMI
patients were randomly assigned to receive either
RIC (n ¼ 258) or the control protocol (n ¼ 261). The
2 groups had similar patient characteristics. AUC
troponin T data were available for 414 patients, and
AUC CK-MB data were available for 407 patients.
Median enzymatic MI size was 32% smaller by 24-h
AUC troponin T and 19% smaller by 24-h AUC CK-MB
in patients who received RIC compared with the con-
trol patients (Table 1).
The ERIC-LYSIS study was the ﬁrst to investigate
the effect of RIC in STEMI patients reperfused by
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2765thrombolysis in a developing nation. We found that
those patients who were randomized to receive RIC
upon arrival at the hospital and before thrombolytic
therapy experienced a signiﬁcant reduction in enzy-
matic MI size compared with the control group. The
size of this cardioprotective effect was comparable to
that observed in STEMI patients treated by PPCI, for
which studies have reported 25% to 30% reductions in
MI size as measured by myocardial single-photon
emission computed tomography and cardiac mag-
netic resonance imaging (3–5). The limitations of our
study include the following: 1) although tissue plas-
minogen activator (t-PA) is the most commonly used
thrombolytic agent in developed countries, strepto-
kinase (which costs 10-fold less than t-PA) continues
to be used in developing nations; and 2) conducting a
randomized control trial in a developing nation with
very limited resources was challenging and explains
in part why we were only able to obtain data on
enzymatic MI size.
In conclusion, we have shown that RIC reduced MI
size in STEMI patients treated with thrombolysis,
making this noninvasive, easily applied, low-cost
therapy an attractive option in developing nations
where health care resources are limited and current
therapy is not optimal.
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178–88.Are Phytosterols
Responsible for
the Low-Density
Lipoprotein–Lowering
Effects of Tree Nuts?
A Systematic Review and Meta-AnalysisIntake of tree nuts is associated with a lower risk of
cardiovascular events in prospective cohorts and
the PREDIMED (Prevención con Dieta Mediterránea)
trial (1). Previous meta-analyses indicated that tree
nut intake lowered low-density lipoprotein (LDL)
cholesterol (2,3). However, few trials (#13 studies)
were included in these meta-analyses; pooled effects
were not standardized to a common dose, which
prevented conclusions about the magnitude of effects
for a given intake of nuts, and speciﬁc constituents in
tree nuts were not examined for their contributions
to this LDL-lowering effect. Tree nuts are rich
in phytosterols that displace cholesterol from intes-
tinal micelles and reduce the pool of absorbable
